Promising cancer research: scientists have engineered ready-to-use T cells that attacked solid tumours in laboratory and mouse studies, potentially opening the door to more accessible cell therapies.
@thecancersurvivorsclub.com
@thecancersurvivorsclub.comPromising cancer research: scientists have engineered ready-to-use T cells that attacked solid tumours in laboratory and mouse studies, potentially opening the door to more accessible cell therapies.
@thecancersurvivorsclub.comCould AI help solve some of cancer’s hardest problems? Arm CEO Rene Haas believes AI could help find a cure within our lifetime as increasingly powerful systems tackle complex cancer biology.
@thecancersurvivorsclub.comEncouraging progress in lymphoma treatment. CAR T-cell therapy, bispecific antibodies and targeted treatments are giving patients more options, including potentially curative treatments.
@thecancersurvivorsclub.comA first for breast cancer treatment. The FDA has approved camizestrant for certain patients, using a blood test to detect treatment resistance before it appears on scans.
@thecancersurvivorsclub.comA major advance for pancreatic cancer. FDA-approved daraxonrasib increased median survival to 13.2 months vs 6.7 months with chemotherapy in a Phase 3 trial.
@thecancersurvivorsclub.comA new approach to treating advanced breast cancer. The FDA has approved Etcamah after a blood test detects an ESR1 resistance mutation, allowing treatment to change before scans show the cancer progressing.
@thecancersurvivorsclub.comSix cancer drug approvals in a single month. August brought new FDA-approved treatment options across pancreatic cancer, gastroesophageal cancer, melanoma, multiple myeloma and rare blood cancers.
@thecancersurvivorsclub.comEncouraging development for daraxonrasib. New trial results suggest the approved pancreatic cancer drug may also have potential against RAS-mutated non-small-cell lung cancer, with tumours shrinking in more than 30% of participants.
@thecancersurvivorsclub.comA personalised cancer vaccine moves another step closer. A late-stage trial of an mRNA vaccine tailored to each patient’s tumour has shown it can reduce the risk of melanoma returning or spreading.